Isomorphic Labs

Private

London-based AI-first drug design and development company spun out of Google DeepMind in 2021. Builds the IsoDDE drug design engine leveraging AlphaFold-derived architectures to design therapeutic candidates across disease areas. CEO Demis Hassabis is also CEO of Google DeepMind.

Founders Demis Hassabis

CEO Demis Hassabis

Company

Founded

2021

Headquarters

London, United Kingdom

Financials

Total Funding

$2.7B

Sectors

Artificial Intelligence Healthtech Biotech

isomorphiclabs.com

Funding History

2 rounds

Series B May 12, 2026

$2.1B

Thrive Capital (Lead) Alphabet GV MGX Temasek Holdings CapitalG UK Sovereign AI Fund

Series A Apr 15, 2025

$600M

Thrive Capital (Lead) Alphabet GV

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.